Multicenter ProKnow-based plan evaluation of postprostatectomy salvage radiotherapy patients using SPPORT and RADICALS-HD trial-defined dose constraints
Michael Keilholz, Erik F. Moar, Sarah Frederike Brose et al. · Strahlentherapie und Onkologie · 2026
Cited by 0 works. doi:10.1007/s00066-026-02584-3
Authors
- Michael Keilholz
- Erik F. Moar
- Sarah Frederike Brose
- Sebastian H. Maier
- Claus Belka
- Paul Rogowski
- Matthias Zähringer
- Jan C. Peeken
- Stephanie E. Combs
- Stephan Schönecker
- Florian Putz
- Christoph Süß
- Marius Treutwein
- Vasiliki Angnostatou
- Nina Schmidt-Hegemann
References
- Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
- Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial
- Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
- The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
- Pathologic findings at radical prostatectomy: Risk factors for failure and death
- Improved Toxicity Profile Following High-Dose Postprostatectomy Salvage Radiation Therapy With Intensity-Modulated Radiation Therapy
- Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
- Clinical Factors Predicting Late Severe Urinary Toxicity After Postoperative Radiotherapy for Prostate Carcinoma: A Single-Institute Analysis of 742 Patients
- Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death